Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results

Author's Avatar
Aug 10, 2021

Marker continues to enroll patients and activate clinical sites in Phase 2 AML trial following completion of safety lead-in

Company's new in-house cGMP manufacturing facility in Houston is fully operational

PR Newswire